IDEXX Introduces New RealPCR Diagnostics for Safeguarding Equine Health

New diagnostics enable early diagnosis of critical equine diseases to help mitigate health risks for patients and financial risks for owners

WESTBROOK, Maine, March 27, 2014—IDEXX Laboratories has introduced new diagnostics for the equine market, including three new RealPCR reproductive panels, the Strangles RealPCR Screen and a RealPCR test for Corynebacterium pseudotuberculosis, or pigeon fever. These new diagnostics help equine veterinarians quickly and accurately diagnose individuals or herds and enable them to more proactively manage the health of the horses under their care. These new panels cast a wider net to identify more pathogens, provide better accuracy and produce more rapid results than current tests.

"The equine RealPCR tests for reproductive health and pigeon fever and the expanded test option for strangles fill an important void in the diagnostic landscape for equine practitioners," said Christian Leutenegger, head of Molecular Diagnostics at IDEXX. “Abortion in the equine industry is a sensitive topic; it leads to significant financial loss for mare owners.

“The three new reproductive panels help veterinarians rapidly assess the infectious components in a lost pregnancy and our PCR strangles panel covers three important infectious organisms compared to just one. These advances, along with our pigeon fever test, improve the diagnostic ability of equine veterinarians to detect clinical infection earlier, better manage outbreaks and better educate clients to strengthen those relationships,” concluded Leutenegger.

RealPCR Abortion, Postpartum Sick Mare and Infertile Mare Panels
PCR tests provide a more definitive determination of the causes of reproductive problems faster than tests that rely on cultures. By detecting a broad number of pathogens, these three new panels help veterinarians determine more quickly whether the cause of reproductive problems is infectious or physiological. Once the cause is determined, practitioners can quickly take measures to quarantine or treat affected mares appropriately.

Strangles RealPCR Screen
The IDEXX Strangles RealPCR Screen allows practitioners to proactively test for all the Streptococcus organisms that can cause a clinical outbreak of strangles—including S. equi subsp. equi, S. equi subsp. zooepidemicus, and S. dysgalactiae subsp. equisimilus. This approach minimizes the chance of false-negative results and ensures the correct diagnosis the first time, so farms can identify asymptomatic carriers and quickly contain and manage outbreaks.

Corynebacterium pseudotuberculosis (Pigeon Fever) RealPCR Test
Increased horse movement has contributed to more cases of pigeon fever. The Corynebacterium pseudotuberculosis RealPCR Test is the only PCR test for pigeon fever. It is faster and more precise than the currently available tests and allows practitioners to more quickly diagnose internal abscess and treat individual horses.

These diagnostics are available by calling IDEXX Reference Laboratories Customer Support at 1-888-433-9987, option 3, option 5.

About IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc. is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and to build more economically successful practices. IDEXX is also a worldwide leader in providing livestock and poultry diagnostic tests and tests for the quality and safety of water and milk. Headquartered in Maine, IDEXX Laboratories employs more than 5,500 people and offers products to customers in more than 175 countries.

Note Regarding Forward-Looking Statements
This news release contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as “expects,” “may,” “anticipates,” “intends,” “would,” “will,” “plans,” “believes,” “estimates,” “should,” and similar words and expressions. These forward-looking statements are based on management's current expectations and beliefs, as well as a number of assumptions concerning future events. These statements are subject to risks, uncertainties, assumptions and other important factors. Readers are cautioned not to put undue reliance on such forward-looking statements because actual results may vary materially from those expressed or implied. The reports filed by the Company pursuant to United States securities laws contain discussions of these risks and uncertainties. The Company assumes no obligation to, and expressly disclaims any obligation to, update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers are advised to review the Company's filings with the United States Securities and Exchange Commission (which are available from the SEC's EDGAR database at sec.gov, at various SEC reference facilities in the United States and via the Company's website).


Contact:

IDEXX Laboratories
Scott Moffitt
Senior Manager of Equine Sales and Marketing
1-336-834-6505
scott-moffitt@idexx.com